{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-049263","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.339008+00:00","generated_at":"2026-06-05T09:42:31.303517+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NewAmsterdam Pharma FY2023 net loss $176.9M; cash $340.5M; expects Phase 3 readouts in 2024","bullets":["FY2023 net loss of $176.9M ($2.15 per share) vs $11.5M loss prior year; revenue fell to $14.1M from $102.7M.","Cash at Dec 31, 2023: $340.5M; proforma cash after Feb 2024 $202M upsized offering ~$500M.","Phase 3 BROOKLYN topline in HeFH expected 3Q2024; BROADWAY in ASCVD expected 4Q2024.","PREVAIL CVOT enrollment to complete 1Q2024; topline data expected 2026. TANDEM FDC trial initiation 1Q2024 with data 1Q2025.","Appointed William H. Lewis as Board Chair; Phase 2 data showed significant LDL-C lowering with placebo-like safety."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-049263","json":"https://secwatch.observer/filing/0001193125-24-049263.json","markdown":"https://secwatch.observer/filing/0001193125-24-049263.md","text":"https://secwatch.observer/filing/0001193125-24-049263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524049263/0001193125-24-049263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524049263/d772021d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:42:31.303517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2501346a25a84d96a6c49950ebf1efb209c5f487","claim":"NewAmsterdam Pharma Co N.V. reported financial results for the full year ended December 31, 2023.","evidence_excerpt":"NewAmsterdam Pharma Company N.V. (the \"Company\") issued a press release announcing corporate updates and its financial results for the full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524049263/0001193125-24-049263-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}